Program
Cyclophosphamide
Also written as “cyclophosphamide”, “Cyclophosphamide,Fludarabine” and “Cytoxan”.
Its studies are mostly in Breast Neoplasms · Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Leukemia, Lymphocytic, Chronic, B-Cell · Carcinoma, Non-Small-Cell Lung, led by 28 companies.
Drug pageCyclophosphamide: every studyMany companies study it; this page follows only the 70 they lead. All 1,538 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 151 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | Feb 28, 2028phase 2 · NCT04931342 |
| Beijing Biotechits history only | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| ImmunoVaccine Technologies, Inc. (IMV Inc.)its history only | 63 open or running | phase 2since Dec 12, 2014 | Dec 12, 2014 | none ahead |
| Amgenits history only | 40 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Sanofiits history only | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Takedaits history only | 41 open or running | phase 2since Jul 25, 2007 | Jul 25, 2007 | none ahead |
| Allogene Therapeuticsits history only | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Bristol-Myers Squibbits history only | 21 open or running | phase 2since Dec 22, 2016 | Dec 22, 2016 | Mar 15, 2029phase 1 · NCT07115745 |
| Hangzhou Huasai Biomedicineits history only | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Rampart Healthits history only | 21 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| Shanghai First Song Biotechnologyits history only | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| Adicet Therapeuticsits history only | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Nov 21, 2017 | Nov 21, 2017 | none ahead |
| Caribou Biosciencesits history only | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| CARsgen Therapeuticsits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Criteriumits history only | 10 open or running | phase 1since Aug 7, 2012 | Aug 7, 2012 | none ahead |
| Gilead Sciences | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Merckits history only | 10 open or running | phase 2since Oct 23, 2008 | Oct 23, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 10 open or running | phase 1since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Neukio Biotherapeutics (Shanghai)its history only | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| Nkartaits history only | 11 open or running | phase 1since Sep 25, 2020 | Sep 25, 2020 | none ahead |
| Oncotherapeuticsits history only | 10 open or running | phase 2since Jul 30, 2014 | Jul 30, 2014 | none ahead |
| Precision BioSciencesits history only | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Sangamo Therapeuticsits history only | 10 open or running | phase 2since Aug 22, 2014 | Aug 22, 2014 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Jun 27, 2007 | Jun 27, 2007 | none ahead |
| Seah Lim M.D.its history only | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| Shanghai Unicar-Therapy Bio-medicine Technologyits history only | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| TTY Biopharmits history only | 10 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
Also a collaborator on its studies: Natera, Incyte, AbbVie and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2017First study: phase 1 study in Multiple MyelomaFirst studyNCT03318861 · 17 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03318861Multiple Myeloma · United States | 1 | Terminated | Dec 17, 2018 | 17 |
How it is read
Names in the registry
- “Cyclophosphamide”, 74 entries
- “cyclophosphamide”, 9 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “Cytoxan”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 9 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 8 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.